4CPS-312 Pharmaceutical interventions in a non-oncohaematological daily hospital

JA Dominguez Menendez, A Revuelta Amallo, C Vila Gallego, M Vara Urruchua, U Blazquez Urtizberea, S Vallinas Hidalgo, E Oñate Muzas, E Tamayo Orbegozo, A Aguirrezabal Arredondo
2021 Section 4: Clinical pharmacy services   unpublished
Results 30 patients were treated with tofacitinib from 2017 to March 2020, 23 women and 7 men, with a median age of 55 (48-62) years; 40% of patients were overweight. 23 patients were diagnosed with rheumatoid arthritis, 3 patients with psoriasis arthritis, 1 patient with vitiligo, 1 patient with alopecia areata and 1 patient with polyarthritis. 50% of patients were pre-exposed to at least one biological agent and all of the patients were pre-exposed to methotrexate, leflunomide and/or
more » ... loroquine. Median time to stop tofacitinib was 307 (114-557) days. Reasons for stopping tofacitinib were: insufficient response (n=9), infection (n=1), headache (n=3), haematemesis (n=1) and pregnancy (n=1). 15 patients have continued treatment with tofacitinib with a good response. Elevation of liver enzymes, or changes in the levels of lymphocytes, neutrophils and haemoglobin have not been detected in any patient. 30% of patients had adverse events; more frequent adverse events were infections in 13% of patients and headache in 13% of patients. Conclusion and relevance The efficacy and safety of tofacitinib have been demonstrated in clinical trials. This retrospective analysis of real life data showed that tofacitinib was also effective and safe in a real life setting but only 50% of the patient cohort achieved a response with a dose of tofacitinib 5 mg twice daily. Due to the size of the group, these results should be interpreted with caution; future analysis in clinical practice is necessary.
doi:10.1136/ejhpharm-2021-eahpconf.144 fatcat:dk46bjeqczcl7mlmro3x53har4